Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
2024年8月22日 - 9:30PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Endovascular Robotic System, announces that it entered
into a Phase 2 collaboration agreement with Corewell
Health™ that will continue their collaboration to advance
remote telesurgery for endovascular procedures. The Company had
previously announced positive results from the first phase, which
demonstrated LIBERTY’s technical capabilities and outlined
potential future applications in a range of endovascular
interventions, including the feasibility of LIBERTY to support the
remote telesurgery project.
During Phase 2, the Company and Corewell Health will work
together to develop the capabilities to perform simulated
cardiovascular interventional procedures with LIBERTY across two
sites within the Corewell Health system which are 5 miles
apart.
The project is led by Ryan Madder, M.D., Section Chief of
Interventional Cardiology and Director of the Cardiac Cath Lab at
Corewell Health in West Michigan. Following the completion of Phase
1, Dr. Madder and colleagues published a manuscript in the Journal
of the American College of Cardiology: Cardiovascular
Interventions, highlighting the Technical Success of Coronary
Guidewire and Stent Delivery Using a Novel Miniaturized Robotic
System in a Pre-Clinical Study.
“Incorporating telesurgery capabilities is an important part of
our long-term strategy for LIBERTY,” said Harel Gadot, CEO,
President and Chairman of Microbot Medical. “We believe that
physicians in the U.S. and around the globe want to increase access
to care for patients in remote locations, and we are excited to
continue our collaboration with Corewell Health and Dr. Madder on
this next phase of development.”
Dr. Madder’s manuscript is available at:
https://doi.org/10.1016/j.jscai.2024.102148
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 8 2024 まで 9 2024
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 9 2023 まで 9 2024